Miso and blood sugar control in type 2 diabetes
What it found
In a cross-sectional study of Japanese patients with type 2 diabetes, women who habitually ate miso soup had lower average HbA1c and less variation in HbA1c than women who did not.
No such link was seen in men.
What they found
Studies in people
HbA1c levels in women
In women, the average HbA1c was lower in those who habitually ate miso soup than in those who did not (7.0% vs. 7.3%). The standard deviation and coefficient of variation of HbA1c were also lower in the habitual miso group.
HbA1c variability in women
After adjusting for factors like age, BMI, diabetes duration, and diet, habitual miso consumption was linked to lower average, standard deviation, and coefficient of variation of HbA1c in women.
No link in men
In men, habitual miso consumption was not associated with any measure of blood sugar control, including average HbA1c, its standard deviation, or its coefficient of variation.
Other measures in women
Women who habitually ate miso soup also had lower fasting blood sugar and a lower percentage of hypertension than those who did not. Their intake of energy, protein, fat, and dietary fiber was higher.
Other findings
Miso types not studied
The study did not look at different types of miso, such as rice koji, barley koji, or soybean koji miso, so it is unclear if the type matters.
What the authors conclude
“This study demonstrated the relationship between habitual miso consumption and glycemic variability in female, but not in male, with T2DM.”
Also in their conclusions
- They conclude that habitual miso consumption is related to better blood sugar control, including less variability, in women with type 2 diabetes but not in men.
- They say that miso soup consumption may help in the management of patients with type 2 diabetes.
- They call for further research, including studies with more participants and randomized clinical trials, to confirm the findings.
How it was done
The authors wanted to know whether habitual miso consumption is related to blood sugar control, including blood sugar variability, in people with type 2 diabetes. Previous work had linked miso soup intake to lower insulin resistance, but the relationship with blood sugar control and variability was unknown.
They studied 290 patients with type 2 diabetes (160 men and 130 women) from two hospitals in Japan. Participants answered a diet questionnaire about the previous month, including how often they ate miso soup, and their HbA1c levels were collected from medical records over a year. Habitual miso consumption meant eating miso soup at least once a day.
What it can’t tell you
- This was a cross-sectional study, so it can show a link between miso consumption and blood sugar control but cannot prove that miso causes better control.
- The study only included Japanese people, so the results may not apply to other ethnic groups.
- The frequency of miso soup intake was self-reported, which may not be accurate.
Who paid
- Funding
- Funded by JSPS KAKENHI (from the PubMed record).
- Conflicts
- Hashimoto reports personal fees from Mitsubishi Tanabe Pharma Corp, Novo Nordisk Pharma Ltd., Sanofi K.K., and Daiichi Sankyo Co. Ltd. outside the submitted work. Senmaru has received personal fees from MSD K.K., Sanofi K.K., Taisho Toyama Pharma Co., Ltd., Ono Pharma Co., Ltd., Mitsubishi Tanabe Pharma Co, Kowa Pharma Co., Ltd., Kyowa Hakko Kirin Co., Ltd., Eli Lilly Japan K.K., Takeda Pharma Co., Ltd., Kissei Pharma Co., Ltd., Astellas Pharma Inc., and Novo Nordisk Pharma Ltd., outside the submitted work. Ushigome received grant support from the Astellas Foundation for Research on Metabolic Disorders and the Japanese Study Group for Physiology and Management of Blood Pressure and received grant from Ono Pharma. Co., Ltd., Mitsubishi Tanabe Pharma Corp., and received personal fees from Novo Nordisk Pharma Ltd., Kowa Pharma Co. Ltd., AstraZeneca plc, Daiichi Sankyo Co. Ltd., Astellas Pharma Inc., Takeda Pharma Co., Ltd., Kyowa Kirin Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., MSD K.K., and Taisho Toyama Pharma Co., Ltd. outside the submitted work. Hamaguchi reports grants from Sanofi K.K., Eli Lilly Japan K.K., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Takeda Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co. Ltd., Mitsubishi Tanabe Pharma Corp, Asahi Kasei Pharma, and Kyowa Kirin Co. Ltd. outside the submitted work. Asano reports honoraria from Ono Pharmaceutical Co., Ltd., Abbott Japan Co., Ltd., AstraZeneca plc, Kowa Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., and Novo Nordisk Pharma Ltd. Yamazaki reports personal fees from, Kowa Pharma Co. Ltd., MSD K.K., Daiichi Sankyo Co. Ltd., AstraZeneca plc., Kowa Pharma Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharma Co. Ltd., and Ono Phama Co., Ltd. outside the submitted work. Prof. Fukui received grants from Astellas Pharma Inc., Tejin Pharma LtD., Kyowa Kirin Co., Ltd., Daiichi Sankyo Co. Ltd., Takeda Pharma Co. Ltd., MSD K.K., Kowa Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Sanofi K.K., Kissei Phama Co. Ltd., Nippon Boehringer Ingelheim Co. Ltd., Ono Pharma Co. Ltd., Sanwa Kagagu Kenkyusho CO., LtD., Mitsubishi Tanabe Pharma Corp, Sumitomo Dainippon Pharma Co., Ltd., Nippon Chemiphar Co., Ltd., Abbott japan Co. Ltd., Taisho Pharma Co., Ltd., Eli Lilly Japan K.K., and Terumo Corp., and received honoraria from Kowa Pharma Co. Ltd., Sanofi K.K., Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Nipro Corp., Ono Pharma Co. Ltd., Teijin Pharma Ltd., Sanwa Kagaku Kenkyusho Co. Ltd., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co. Ltd., Medtronic Japan Co. Ltd., Johnson & Johnson k.k. Medical Co., Astellas Pharma Inc., Taisho Pharma Co., Ltd., Arkray Inc., Bayer Yakuhin, Ltd., AstraZeneca K.K., Kissei Pharma Co., Ltd., Eli Lilly Japan K.K., Mochida Pharma Co. Ltd., Abbott japan Co. Ltd., MSD K.K., and Takeda Pharma Co. Ltd. outside the submitted work. The other authors have nothing to disclose.
- Authors work at
- Kyoto Prefectural University of Medicine, Japan; Kameoka Municipal Hospital, Japan; Matsushita Memorial Hospital, Japan
The paper
- Title
- Habitual Miso (Fermented Soybean Paste) Consumption Is Associated with Glycemic Variability in Patients with Type 2 Diabetes: A Cross-Sectional Study
- Type
- Study
- Evidence
- Studies in people
- Summarised from
- Full text
- Licence
- CC BY. Words in quotation marks are the authors’; the rest is our summary.
- Cite
- Takahashi F, Hashimoto Y, Kaji A, et al (2021). Habitual Miso (Fermented Soybean Paste) Consumption Is Associated with Glycemic Variability in Patients with Type 2 Diabetes: A Cross-Sectional Study. Nutrients. doi:10.3390/nu13051488Free full textPubMed 33924846DOI
Summary written 30 Sep 2026. Check it against the paper before it changes what you eat. How we summarise papers · Report an error